Head-to-head evidence
ISC-hpNSC vs OK99
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: neural stem cell therapy · full Parkinson's Disease pipeline
ISC-hpNSC
Developed by Cyto Therapeutics Pty Limited and partners
NCT02452723 · Phase 1 · completed
This was a small, open-label, single-arm safety study of a stem-cell transplant procedure, with no randomization or control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
OK99
Developed by Celavie Biosciences, LLC
NCT02780895 · Phase 1 · status unknown
This was an uncontrolled, open-label surgical study in only 8 patients, with no comparator group and no blinding, so it cannot show a treatment effect distinct from surgical or placebo effects; no results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ISC-hpNSC's landscape · OK99's landscape